A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
Pfizer
Pfizer
NRG Oncology
Novartis
AstraZeneca
Stemline Therapeutics, Inc.
Merck Sharp & Dohme LLC
Ellipses Pharma
Eli Lilly and Company
Olema Pharmaceuticals, Inc.
Eli Lilly and Company
University of Virginia
Shandong Suncadia Medicine Co., Ltd.
Fudan University
Ente Ospedaliero Ospedali Galliera
Japanese Foundation for Cancer Research
Jiangsu Simcere Pharmaceutical Co., Ltd.
European Organisation for Research and Treatment of Cancer - EORTC
Washington University School of Medicine
AstraZeneca
UNC Lineberger Comprehensive Cancer Center
Fudan University